Full Text Journal Articles by
Author Celestia S Higano

Advertisement

Find full text journal articles






Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.

Celestia S Higano,

PURPOSE:Androgen deprivation therapy (ADT), a mainstay of therapy for advanced prostate cancer (CaP), may raise patients' risk of cardiovascular disease (CVD) and related adverse events. The new androgen receptor (AR)-targeted agents are associated with hypertension and cardiovascular events. The most common non-CaP cause of death in men with CaP is ... Read more >>

Urol. Oncol. (Urologic oncology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.

Wassim Abida, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H Bryce, Ray McDermott, Brieuc Sautois, Nicholas J Vogelzang, Richard M Bambury, Eric Voog, Jingsong Zhang, Josep M Piulats, Charles J Ryan, Axel S Merseburger, Gedske Daugaard, Axel Heidenreich, Karim Fizazi, Celestia S Higano, Laurence E Krieger, Cora N Sternberg, Simon P Watkins, Darrin Despain, Andrew D Simmons, Andrea Loehr, Melanie Dowson, Tony Golsorkhi, Simon Chowdhury, ,

PURPOSE:BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We present results from patients with mCRPC associated with a BRCA alteration treated with rucaparib 600 mg twice daily in the phase II TRITON2 study. METHODS:We enrolled ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO2001035]

Cited: 0 times

View full text PDF listing >>



Advertisement

Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer.

Marlon Perera, Matthew J Roberts, Laurence Klotz, Celestia S Higano, Nathan Papa, Shomik Sengupta, Damien Bolton, Nathan Lawrentschuk,

Androgen deprivation therapy (ADT) is still a mainstay of treatment for advanced prostate cancer. Continuous ADT causes considerable patient morbidity including sexual dysfunction, poor mood and physical capacity, changes in body composition and health-care-related costs. Intermittent ADT has been used as an approach to ADT monotherapy to limit morbidity by ... Read more >>

Nat Rev Urol (Nature reviews. Urology)
[2020, 17(8):469-481]

Cited: 0 times

View full text PDF listing >>



Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.

Andrew J Armstrong, Ping Lin, Bertrand Tombal, Fred Saad, Celestia S Higano, Anthony M Joshua, Teresa Parli, Brad Rosbrook, Steve van Os, Tomasz M Beer,

BACKGROUND:In the PREVAIL study, enzalutamide significantly improved clinical outcomes versus placebo in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE:To evaluate long-term benefits and risks of enzalutamide in the final prespecified PREVAIL analysis. DESIGN, SETTING, AND PARTICIPANTS:We conducted a final 5-yr survival analysis of PREVAIL in men with chemotherapy-naïve ... Read more >>

Eur. Urol. (European urology)
[2020, 78(3):347-357]

Cited: 0 times

View full text PDF listing >>



Cardiovascular Disease and Androgen Axis-Targeted Drugs for Prostate Cancer.

Celestia S Higano,

N. Engl. J. Med. (The New England journal of medicine)
[2020, 382(23):2257-2259]

Cited: 0 times

View full text PDF listing >>



Pearls to Pivoting a Multidisciplinary Prostate Cancer Survivorship Program During the COVID-19 Pandemic.

Ryan Flannigan, Monita Sundar, Sarah Weller, Nikita Ivanov, Monica Hu, Marcy Dayan, Charlene Chen, Eugenia Wu, Larry Goldenberg, Celestia S Higano,

Eur Urol Oncol (European urology oncology)
[2020, 3(4):397-399]

Cited: 0 times

View full text PDF listing >>



Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.

Neal Shore, Celestia S Higano, Daniel J George, Cora N Sternberg, Fred Saad, Bertrand Tombal, Kurt Miller, Jan Kalinovsky, XiaoLong Jiao, Krishna Tangirala, Oliver Sartor,

BACKGROUND:In this study, we evaluated real-world data on radium-223 plus abiraterone/prednisone or enzalutamide. Previously, the ERA 223 trial (NCT02043678) demonstrated increased fracture risk with concurrent treatment with radium-223 and abiraterone plus prednisone/prednisolone in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS:We used the Flatiron Health database to perform a retrospective ... Read more >>

Prostate Cancer Prostatic Dis. (Prostate cancer and prostatic diseases)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.

Oliver Sartor, Andrew J Armstrong, Chiledum Ahaghotu, David G McLeod, Matthew R Cooperberg, David F Penson, Philip W Kantoff, Nicholas J Vogelzang, Arif Hussain, Christopher M Pieczonka, Neal D Shore, David I Quinn, Eric J Small, Elisabeth I Heath, Ronald F Tutrone, Paul F Schellhammer, Matthew Harmon, Nancy N Chang, Nadeem A Sheikh, Bruce Brown, Stephen J Freedland, Celestia S Higano,

PURPOSE:African Americans experience greater prostate cancer risk and mortality than do Caucasians. An analysis of pooled phase III data suggested differences in overall survival (OS) between African American and Caucasian men receiving sipuleucel-T. We explored this in PROCEED (NCT01306890), an FDA-requested registry in over 1900 patients with metastatic castration-resistant prostate ... Read more >>

Prostate Cancer Prostatic Dis. (Prostate cancer and prostatic diseases)
[2020, 23(3):517-526]

Cited: 0 times

View full text PDF listing >>



Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.

Celestia S Higano, Andrew J Armstrong, Oliver Sartor, Nicholas J Vogelzang, Philip W Kantoff, David G McLeod, Christopher M Pieczonka, David F Penson, Neal D Shore, Jeffrey Vacirca, Raoul S Concepcion, Ronald F Tutrone, Luke T Nordquist, David I Quinn, Vahan Kassabian, Mark C Scholz, Matt Harmon, Robert C Tyler, Nancy N Chang, Hong Tang, Matthew R Cooperberg,

Cancer (Cancer)
[2020, 126(12):2935-2937]

Cited: 0 times

View full text PDF listing >>



Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.

Wassim Abida, David Campbell, Akash Patnaik, Jeremy D Shapiro, Brieuc Sautois, Nicholas J Vogelzang, Eric G Voog, Alan H Bryce, Ray McDermott, Francesco Ricci, Julie Rowe, Jingsong Zhang, Josep Maria Piulats, Karim Fizazi, Axel S Merseburger, Celestia S Higano, Laurence E Krieger, Charles J Ryan, Felix Y Feng, Andrew D Simmons, Andrea Loehr, Darrin Despain, Melanie Dowson, Foad Green, Simon P Watkins, Tony Golsorkhi, Simon Chowdhury,

PURPOSE:Genomic alterations in DNA damage repair (DDR) genes other than BRCA may confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate cancer (mCRPC). To test this hypothesis, the phase II TRITON2 study of rucaparib included patients with mCRPC and deleterious non-BRCA DDR gene alterations. PATIENTS AND METHODS:TRITON2 enrolled patients ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, 26(11):2487-2496]

Cited: 3 times

View full text PDF listing >>



Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel.

Susan Halabi, Sandipan Dutta, Catherine M Tangen, Mark Rosenthal, Daniel P Petrylak, Ian M Thompson, Kim N Chi, Johann S De Bono, John C Araujo, Christopher Logothetis, Mario A Eisenberger, David I Quinn, Karim Fizazi, Michael J Morris, Celestia S Higano, Ian F Tannock, Eric J Small, William Kevin Kelly,

There are few data regarding disparities in overall survival (OS) between Asian and white men with metastatic castration-resistant prostate cancer (mCRPC). We compared OS of Asian and white mCRPC men treated in phase III clinical trials with docetaxel and prednisone (DP) or a DP-containing regimen. Individual participant data from 8820 ... Read more >>

JNCI Cancer Spectr (JNCI cancer spectrum)
[2020, 4(2):pkaa003]

Cited: 0 times

View full text PDF listing >>



Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.

Daniel J George, Oliver Sartor, Kurt Miller, Fred Saad, Bertrand Tombal, Ján Kalinovský, Xiaolong Jiao, Krishna Tangirala, Cora N Sternberg, Celestia S Higano,

BACKGROUND:Clinical trials have demonstrated the efficacy of several life-prolonging therapies for metastatic castration-resistant prostate cancer (mCRPC); however, real-world data on their use, survival effect, and safety are limited. Using electronic health record data from the Flatiron Health database, we studied real-world treatment patterns and health outcomes in patients with mCRPC. ... Read more >>

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2020, 18(4):284-294]

Cited: 0 times

View full text PDF listing >>



Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer.

Daniel C Danila, Russell Z Szmulewitz, Ulka Vaishampayan, Celestia S Higano, Ari D Baron, Houston N Gilbert, Flavia Brunstein, Marija Milojic-Blair, Bei Wang, Omar Kabbarah, Michael Mamounas, Bernard M Fine, Daniel J Maslyar, Alexander Ungewickell, Howard I Scher,

PURPOSE:Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) is highly expressed in prostate cancers. DSTP3086S is a humanized immunoglobulin G1 anti-STEAP1 monoclonal antibody linked to the potent antimitotic agent monomethyl auristatin E. This study evaluated the safety and activity of DSTP3086S in patients with metastatic castration-resistant prostate cancer. METHODS:Patients were ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2019, 37(36):3518-3527]

Cited: 1 time

View full text PDF listing >>



The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.

E David Crawford, Przemyslaw W Twardowski, Raoul S Concepcion, Jason M Hafron, Richard G Harris, Judd W Moul, Lucio N Gordan, Daniel P Petrylak, Stuart N Atkinson, Deborah M Boldt-Houle, Thomas E Keane, Celestia S Higano, R Jonathan Henderson, A Karim Kader, Maha H Hussain, Neal D Shore,

PURPOSE:We evaluated the timeliness of androgen deprivation therapy dosing, the impact of dosing nonadherence on testosterone, and the frequency of testosterone and prostate specific antigen testing in patients with prostate cancer. MATERIALS AND METHODS:We retrospectively analyzed the records of 22,860 patients with prostate cancer treated with luteinizing hormone-releasing hormone agonists. ... Read more >>

J. Urol. (The Journal of urology)
[2020, 203(4):743-750]

Cited: 0 times

View full text PDF listing >>



Current recommendations for prostate cancer genetic testing: NCCN prostate guideline.

James L Mohler, Celestia S Higano, Edward M Schaeffer, Heather H Cheng,

DNA sequencing has become less expensive and patients are requesting sequence information more often. The clinical utility of identifying genomic and/or somatic mutations remains uncertain in most cancers and especially in prostate cancer. However, clinical guidelines must offer guidance. The rapidly expanding knowledge base requires that guideline panels pay vigilant ... Read more >>

Can J Urol (The Canadian journal of urology)
[2019, 26(5 Suppl 2):34-37]

Cited: 0 times

View full text PDF listing >>



Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.

Celestia S Higano, Andrew J Armstrong, A Oliver Sartor, Nicholas J Vogelzang, Philip W Kantoff, David G McLeod, Christopher M Pieczonka, David F Penson, Neal D Shore, Jeffrey Vacirca, Raoul S Concepcion, Ronald F Tutrone, Luke T Nordquist, David I Quinn, Vahan Kassabian, Mark C Scholz, Matt Harmon, Robert C Tyler, Nancy N Chang, Hong Tang, Matthew R Cooperberg,

BACKGROUND:The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). METHODS:PROCEED enrolled patients with mCRPC receiving 3 biweekly sipuleucel-T infusions. Assessments included overall survival (OS), serious adverse events (SAEs), cerebrovascular events (CVEs), and anticancer ... Read more >>

Cancer (Cancer)
[2019, 125(23):4172-4180]

Cited: 3 times

View full text PDF listing >>



Back to Basics: Addressing Bone Health in Men with Prostate Cancer on Androgen Deprivation Therapy.

Alicia K Morgans, Celestia S Higano,

Eur Urol Oncol (European urology oncology)
[2019, 2(5):562-564]

Cited: 0 times

View full text PDF listing >>



Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.

Mark P Labrecque, Ilsa M Coleman, Lisha G Brown, Lawrence D True, Lori Kollath, Bryce Lakely, Holly M Nguyen, Yu C Yang, Rui M Gil da Costa, Arja Kaipainen, Roger Coleman, Celestia S Higano, Evan Y Yu, Heather H Cheng, Elahe A Mostaghel, Bruce Montgomery, Michael T Schweizer, Andrew C Hsieh, Daniel W Lin, Eva Corey, Peter S Nelson, Colm Morrissey,

Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with diverse drivers of disease progression and mechanisms of therapeutic resistance. We conducted deep phenotypic characterization of CRPC metastases and patient-derived xenograft (PDX) lines using whole genome RNA sequencing, gene set enrichment analysis and immunohistochemistry. Our analyses revealed five mCRPC phenotypes ... Read more >>

J. Clin. Invest. (The Journal of clinical investigation)
[2019, 129(10):4492-4505]

Cited: 4 times

View full text PDF listing >>



Germline and Somatic Mutations in Prostate Cancer for the Clinician.

Heather H Cheng, Alexandra O Sokolova, Edward M Schaeffer, Eric J Small, Celestia S Higano,

It is increasingly important for clinicians involved in the management of prostate cancer to understand the relevance of heritable (germline) mutations that, for select patients, affect prostate cancer risk and cancer biology, and acquired (somatic) mutations that occur in prostate cancer cells. In the advanced disease setting, mutations in homologous ... Read more >>

J Natl Compr Canc Netw (Journal of the National Comprehensive Cancer Network : JNCCN)
[2019, 17(5):515-521]

Cited: 0 times

View full text PDF listing >>



A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantation.

Evandro D Bezerra, Mary E Flowers, Lynn E Onstad, Deborah Chielens, Jerald Radich, Celestia S Higano,

CML therapy has improved dramatically with the development of tyrosine kinase inhibitors (TKIs). Prior to the TKI era, we conducted two trials of alpha-interferon (IFN) for post-transplant hematologic and cytogenetic relapse. The complete cytogenetic response rate was 33% and 57% respectively. This report describes a third trial in which 40 ... Read more >>

Leuk. Lymphoma (Leukemia & lymphoma)
[2019, 60(11):2754-2761]

Cited: 0 times

View full text PDF listing >>



Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

Channing J Paller, Emmanuel S Antonarakis, Tomasz M Beer, Hala T Borno, Maria I Carlo, Daniel J George, Julie N Graff, Shilpa Gupta, Elisabeth I Heath, Celestia S Higano, Rana R McKay, Alicia K Morgans, Akash Patnaik, Daniel P Petrylak, Matthew B Rettig, Charles J Ryan, Mary-Ellen Taplin, Young E Whang, Jacob Vinson, Heather H Cheng, Veda N Giri, ,

BACKGROUND:Germline genetic testing increasingly identifies advanced prostate cancer (PCa) patients who are candidates for precision therapies. The Prostate Cancer Clinical Trials Consortium (PCCTC) established the Germline Genetics Working Group to provide guidance and resources to expand effective use of germline genetic testing. MATERIALS AND METHODS:A 14-item questionnaire was e-mailed to ... Read more >>

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2019, 17(4):275-282.e1]

Cited: 0 times

View full text PDF listing >>



Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

James L Mohler, Emmanuel S Antonarakis, Andrew J Armstrong, Anthony V D'Amico, Brian J Davis, Tanya Dorff, James A Eastham, Charles A Enke, Thomas A Farrington, Celestia S Higano, Eric Mark Horwitz, Michael Hurwitz, Joseph E Ippolito, Christopher J Kane, Michael R Kuettel, Joshua M Lang, Jesse McKenney, George Netto, David F Penson, Elizabeth R Plimack, Julio M Pow-Sang, Thomas J Pugh, Sylvia Richey, Mack Roach, Stan Rosenfeld, Edward Schaeffer, Ahmad Shabsigh, Eric J Small, Daniel E Spratt, Sandy Srinivas, Jonathan Tward, Dorothy A Shead, Deborah A Freedman-Cass,

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic ... Read more >>

J Natl Compr Canc Netw (Journal of the National Comprehensive Cancer Network : JNCCN)
[2019, 17(5):479-505]

Cited: 33 times

View full text PDF listing >>



Impact of androgen deprivation therapy on mood, cognition, and risk for AD.

Monique M Cherrier, Celestia S Higano,

Prostate cancer is the most common form of cancer diagnosed in men. Androgen deprivation therapy (ADT) is commonly prescribed, with some estimates indicating over 50% of men with prostate cancer receive ADT at some point in their treatment. Men on ADT are typically otherwise healthy, with good long-term survival. However, ... Read more >>

Urol. Oncol. (Urologic oncology)
[2020, 38(2):53-61]

Cited: 1 time

View full text PDF listing >>



Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.

Susan Halabi, Sandipan Dutta, Catherine M Tangen, Mark Rosenthal, Daniel P Petrylak, Ian M Thompson, Kim N Chi, John C Araujo, Christopher Logothetis, David I Quinn, Karim Fizazi, Michael J Morris, Mario A Eisenberger, Daniel J George, Johann S De Bono, Celestia S Higano, Ian F Tannock, Eric J Small, William Kevin Kelly,

PURPOSE:Several studies have reported that among patients with localized prostate cancer, black men have a shorter overall survival (OS) time than white men, but few data exist for men with advanced prostate cancer. The primary goal of this analysis was to compare the OS in black and white men with ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2019, 37(5):403-410]

Cited: 5 times

View full text PDF listing >>



Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.

Andrew J Armstrong, Ping Lin, Celestia S Higano, Peter Iversen, Cora N Sternberg, Bertrand Tombal, De Phung, Teresa Parli, Andrew Krivoshik, Tomasz M Beer,

BACKGROUND:In the PREVAIL study, enzalutamide provided significant improvements versus placebo in clinical outcomes in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC). The association of post-treatment prostate-specific antigen (PSA) decline with clinical outcomes may provide important prognostic information. OBJECTIVE:To evaluate associations between the magnitude of PSA decline from baseline to ... Read more >>

Eur Urol Oncol (European urology oncology)
[2019, 2(6):677-684]

Cited: 1 time

View full text PDF listing >>



Advertisement

Disclaimer
1.0946 s